{
  "id": 1471834,
  "title": "H.C. Wainwright reiterates Celcuity stock rating on pricing update",
  "url": "https://urgent.news/2026/08/17/h-c-wainwright-reiterates-celcuity-stock-rating-on-pricing-update",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T11:28:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-celcuity-stock-rating-on-pricing-update-93CH-4862772"
  },
  "original_language": "en",
  "account": "Investing.com reports that H.C. Wainwright has reaffirmed its Buy rating and $155 price target for Celcuity Inc (NASDAQ:CELC) following the company's strong second-quarter performance. Despite the stock surging 78% over the past year to $92, InvestingPro data indicates the shares are currently overvalued relative to its Fair Value estimate. Analysts maintain a Strong Buy consensus with target prices ranging from $140 to $178. Celcuity disclosed a wholesale acquisition cost of $10,000 per vial and $30,000 per cycle, with management expecting a gross-to-net ratio of approximately 80%. The National Comprehensive Cancer Network has named the REVTORPYK regimens as preferred Category 1 options for wild-type patients in second-line settings. Celcuity has secured coverage across more than 90% of medical-benefit lives ahead of approval and plans to launch its breast cancer drug REVTORPYK via an expanded access program, with commercial shipments expected to begin in late third-quarter 2026.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target",
        "url": "https://urgent.news/2026/08/17/h-c-wainwright-reiterates-alumis-stock-rating-at-neutral-25-target",
        "published": "2026-08-17T11:29:03.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}